Apogee Therapeutics to report phase 2 trial data on May 27

May 26, 2026 4:01 PM

Apogee Therapeutics Inc. (NASDAQ: APGE) will report 16-week data from Part B of its Phase 2 APEX trial of zumilokibart ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found